TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05427383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026/Placbo Injection
Description: IV KN026/Placebo at 30 mg/kg on D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026/Placbo Injection
Description: IV KN026/Placebo at 30 mg/kg on D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Injection
Description: IV Paclitaxel at 175 mg/m² on D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Injection
Description: IV Paclitaxel at 175 mg/m² on D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Injection
Description: IV Docetaxel at 75 mg/m² on D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel Injection
Description: IV Docetaxel at 75 mg/m² on D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Injection
Description: IV Irinotecan at 125 mg/m² on D1, D8, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Injection
Description: IV Irinotecan at 125 mg/m² on D1, D8, Q3W
Study: NCT05989893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language-based tasks
Description: In either the MRI suite, or the Epilepsy Monitoring Unit, or the operating room, epilepsy and tumor subjects are asked to perform a variety of language-based tasks as neural recordings are made from and/or neural stimulations are delivered to various language areas of the brain.
Study: NCT05651230

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rhamnan sulfate
Description: A randomized, placebo-controlled, double-blind crossover dietary supplement intervention consisting of 3 weeks each of rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) or placebo with 2 weeks of washout between the interventions will be conducted. Dietary supplements (rhamnan sulfate) will be taken orally three time daily at each meal time. Rhamnan sulfate is a polysaccharide (carbohydrate) extracted from seaweeds and can be considered nutrition supplement. As each pill contains 90 mg of rhamnan sulfate or placebo, subjects will be taking 2 pills before or during each meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rhamnan sulfate
Description: A randomized, placebo-controlled, double-blind crossover dietary supplement intervention consisting of 3 weeks each of rhamnan sulfate (Rhamnox100, Konan Chemical Manufacturing Co. LTD, Mie, Japan: 540 mg/day) or placebo with 2 weeks of washout between the interventions will be conducted. Dietary supplements (rhamnan sulfate) will be taken orally three time daily at each meal time. Rhamnan sulfate is a polysaccharide (carbohydrate) extracted from seaweeds and can be considered nutrition supplement. As each pill contains 90 mg of rhamnan sulfate or placebo, subjects will be taking 2 pills before or during each meal.
Study: NCT06295653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement and soft tissue augmentation with Autogenous Subepithelial Connective Tissue Graft or Amniotic Chorion Membrane
Description: assess the efficacy of the peri-implant mucosal thickness enhancement following either subepithelial connective tissue grafts or Amniotic Chorion Membrane placed simultaneously with dental implant placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement and soft tissue augmentation with Autogenous Subepithelial Connective Tissue Graft or Amniotic Chorion Membrane
Description: assess the efficacy of the peri-implant mucosal thickness enhancement following either subepithelial connective tissue grafts or Amniotic Chorion Membrane placed simultaneously with dental implant placement.
Study: NCT05948618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agent
Description: The ECA- PRO measures will included PROMIS Profile measures, which include depression, anxiety, fatigue, pain intensity, and interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. In order to reduce boredom and confusion, equivalent forms of different items will be selected from the items pools. In this way, participants are not answering the same questions twice within one session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REDCap Survey
Description: An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
Study: NCT06422143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sac-TMT
Description: IV infusion
Study: NCT05215353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Participants will receive seven weekly 60-minute treatments of music therapy. All sessions will be delivered virtually through Zoom.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Participants will receive seven weekly 60-minute treatment of cognitive behavioral therapy. All sessions will be delivered virtually through Zoom.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessments
Description: Participants will complete study assessments prior to randomization (week 0) and at weeks 4, 8, 16, and 26. A subgroup of 60 survivors will complete optional semi-structured interviews after treatment to understand their unique experiences with MT or CBT. All participants will be followed for 26 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessments
Description: Participants will complete study assessments prior to randomization (week 0) and at weeks 4, 8, 16, and 26. A subgroup of 60 survivors will complete optional semi-structured interviews after treatment to understand their unique experiences with MT or CBT. All participants will be followed for 26 weeks.
Study: NCT05847166

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [99mTc]Tc-PSMA-T4
Description: \[99mTc\]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The \[99mTc\]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product \[99mTc\]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [99mTc]Tc-PSMA-T4
Description: \[99mTc\]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The \[99mTc\]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product \[99mTc\]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [99mTc]Tc-PSMA-T4
Description: \[99mTc\]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The \[99mTc\]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product \[99mTc\]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.
Study: NCT05162846

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Publicly available genetic testing resources
Description: Participants may view the publicly available Michigan Department of Health and Human Services (MDHHS) website as they wish.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual genetics navigator
Description: A mobile-optimized website/online genetic tool developed by investigators from the University of Michigan's Center for Health Communications Research (CHCR).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Description: At least 2 phone calls delivered by trained genetic health coaches using motivational interviewing and providing genetic testing information.
Study: NCT05890001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI5100
Description: Patients will take BLI5100 once daily, orally, for up to 29 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI5100
Description: Patients will take BLI5100 once daily, orally, for up to 29 weeks.
Study: NCT06171685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teclistamab Monotherapy
Description: standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: investigational doses compared to SOC
Study: NCT05838313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elective Induction of Labor Decision Support Tool
Description: Decision support tool for people having their first baby and planning vaginal delivery without a medical indication for induction of labor
Study: NCT05723653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project nGage
Description: Project nGage (nGage) is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among young Black sexual minority men. The nGage intervention consists of (1) selection and invitation of a Support Confidant (SC), (2) a face-to-face intervention between the Intervention Case Manager and the Index and SC, and (3) quarterly interactive mini-booster sessions delivered to the Index and SC via text or telephone, based on participant preference.
Study: NCT05962489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinically optimized deep brain stimulation
Description: Participants will have DBS implanted as standard-of-care. We will be examining the effects of their regular clinical stimulation settings versus no stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinically optimized deep brain stimulation
Description: Participants will have DBS implanted as standard-of-care. We will be examining the effects of their regular clinical stimulation settings versus no stimulation.
Study: NCT05447663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siremadlin
Description: Siremadlin was administered at a starting dose of 30 mg/day on days 1-5 of a 28-day treatment cycle (Part 1).
Study: NCT05348733

Intervention type: DRUG
Intervention: Kerendia (Finerenone, BAY94-8862)
Description: Decision will taken by the treating physician to initiate treatment with finerenone.
Study: NCT05427123

Intervention type: OTHER
Intervention: Medication or psychosocial treatment
Description: Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
Study: NCT05589389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Healthy Eating Index Diet with Minimally Processed Meat
Description: Participants will consume a diet with a high Healthy Eating Index along with meat that is minimally processed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Healthy Eating Index Diet with Further Processed Meat
Description: Participants will consume a diet with a high Healthy Eating Index along with meat that is further processed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Typical Healthy Eating Index Diet with Minimally Processed Meat
Description: Participants will consume a diet with a typical Healthy Eating Index along with meat that is minimally processed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Typical Healthy Eating Index Diet with Further Processed Meat
Description: Participants will consume a diet with a typical Healthy Eating Index along with meat that is further processed.
Study: NCT06454812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical vibration
Description: The vibration device will be placed on the procedure site (on the vastus lateralis muscle) on the left extremity and fixed through a long gauze. The vibration device will be operated for 30 seconds with reference to previous studies, then the nurse will administer routine intramuscular Hepatitis B vaccine. A gap of approximately 1-2 cm will be left between the device and the injection site. After the vaccination procedure is completed, the vibration will be terminated. The same procedure was repeated for DTaP-IPV-Hib vaccine administered to the the right extremity. The baby will be swaddled and placed in the mother's lap.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helfer skin tap technique (HSTT)
Description: In this group, HSTT consisting of 4-stage strokes will be applied to the vaccination site. The nurse will make approximately 10 strokes for 5 seconds with the palmar side of the fingers of the dominant hand to the injection site to relax the muscles (Stage 1). The nurse will give a V-shaped position to the thumb and index finger of the non-dominant hand and give 3 strokes to the injection site with the palmar side of the fingers (Stage 2). The skin entry site of the needle will remain inside the V-shape. Simultaneously with the 3rd stroke, the nurse will insert the needle into the muscle at a 90 degree angle. The nurse will inject the vaccine into the muscle while continuing to tap the skin with the palmar side of the fingers of the non-dominant hand (Stage 3). The nurse will make 3 strokes on the skin with the palmar side of the fingers of the non-dominant hand at the injection site, simultaneously with the 3rd stroke, the needle will be removed from the baby's skin (Stage 4).
Study: NCT05410418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Mosunetuzumab is administered subcutaneously using a step-up dosing strategy. The initial dose on C1D1 will be 5 mg, and doses thereafter will be 45 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab vedotin is administered intravenously over 90 minutes for the initial dose, and over 30 minutes thereafter.
Study: NCT05100342

Intervention type: DIAGNOSTIC_TEST
Intervention: Point score prediction tool for 30-day survival
Description: This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days

Intervention type: DIAGNOSTIC_TEST
Intervention: Point score prediction tool for 30-day survival
Description: This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days

Intervention type: DIAGNOSTIC_TEST
Intervention: Point score prediction tool for 30-day survival
Description: This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score.~The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days
Study: NCT06356311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Participants will receive sacituzumab tirumotecan as 4mg/kg IV infusion on days 1, 15, and 29 of every 42-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine-Tipiracil
Description: Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan will be administered at a dose of 150 mg/m\^2 by IV infusion on days 1 and 15 of every 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 mg/m\^2 by IV infusion on days 1, 8 and 15 of every 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administered at a dose of 75 mg/m\^2 by IV infusion on day 1 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supportive care measures
Description: Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive care measures
Description: Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
Study: NCT05589311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transformative Learning principles
Description: Transformative Learning principles are incorporated into the pain education workshop to stimulate critical reflection and critical discourse during the learning process.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional didactic approach
Description: The conventional didactic approach focuses on lecture-based instruction as the teaching center, emphasizing the delivery of syllabus and concept.
Study: NCT04887077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kiplin
Description: The Kiplin intervention will be composed of four components within a smartphone application: a) a gamification of Physical Activity through multiple games called animations, b) a remote adapted physical activity program with telecoaching sessions, c) an interface for exchange and conversation and, d) an activity monitoring tool.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: face-to-face
Description: three-month program of face-to-face adapted physical activity, three sessions a week, for a total of 36 sessions.
Study: NCT06217653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mother baby yoga
Description: Yoga Video Content Plan~* Mood Regulation: Abdominal/Belly Breathing~* Warm Touch from the Heart~* Chair Posture~* Bucket Wrapping~* Bukka Bukka (Heart)~* Vortex Generation~* Fertile Falls~* One Hand Two Hands~* Tiny Stretches~* Here and Now Awareness~* Dolphin Pose Mothers were asked to choose the most suitable time of the day for the baby and herself, to have the baby fed at least 45 minutes before yoga, and to practice in a calm and dim environment, listening to music or white noise of her choice. Approximately one yoga session is 20 minutes.
Study: NCT05561426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum breakfast and dinner meals for 12 days
Description: Ad libitum portions of breakfast and dinner meals served at the eating behaviour lab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum breakfast and dinner meals for 12 days
Description: Ad libitum portions of breakfast and dinner meals served at the eating behaviour lab
Study: NCT05677698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lemon oil
Description: Lemon oil with massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peppermint oil
Description: peppermint oil with massage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Almond oil
Description: Almond oil massage